The Austin-based stroke-device maker plans to market 10 million shares at $14 to $16 each, according to a filing submitted Monday to the US Securities and Exchange Commission.
At the top of the range, Mobia would be valued at about $529 million based on the outstanding shares listed in the filing.
The offering would provide fresh capital for a company focused on medical devices designed to help stroke survivors.
With a single product and uncertain reimbursement, is Mobia's half-billion-dollar IPO valuation built on solid ground?
As AI transforms neurorehab, is Mobia's invasive implant a breakthrough or an expensive detour for stroke patients?